Characterization and development of a peptide (p160) with affinity for neuroblastoma cells

Journal of Nuclear Medicine

Volumn 47, Issue 6, 2006, Pages 981-988

  Askoxylakis, Vasileios ^a   Mier, Walter ^a   Zitzmann, Sabine ^a   Ehemann, Volker ^a   Zhang, Jianbing ^b   Krämer, Susanne ^a   Beck, Carmen ^a   Schwab, Manfred ^c   Eisenhut, Michael ^c   Haberkorn, Uwe ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Neuroblastoma; Peptide; Tumor affinity

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; GLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGINYLPHENYLALANYLLEUCINE I 125; PEPTIDE; RADIOPHARMACEUTICAL AGENT; TRYPTOPHANYLMETHIONYLGLUTAMYLPROLYL BETA ALANYLTYROSYLGLUTAMINYLARGININE I 125; TRYPTOPHANYLMETHIONYLGLUTAMYLPROLYL BETA ALANYLTYROSYLGLUTAMINYLARGININE I 131; TRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGININE I 125; TRYPTOPHANYLNORLEUCYLGLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGININE I 125; UNCLASSIFIED DRUG; VALYLPROLYLTRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLALANYLTYROSINE I 125; VALYLPROLYLTRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGINYLPHENYLALANYLLEUCINE; VALYLPROLYLTRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGINYLPHENYLALANYLLEUCINE I 125; VALYLPROLYLTRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLALANYLTYROSYLGLUTAMINYLARGINYLPHENYLALANYLLEUCINE I 131; DIAGNOSTIC AGENT; MYBBP1A PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CELL CULTURE; METABOLIC CLEARANCE RATE; METABOLISM; PROTEIN BINDING; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; FEMALE; HUMANS; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NEUROBLASTOMA; NUCLEAR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; ORGAN SPECIFICITY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 33746061739     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140.
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
3. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001;85:266-272.
4. Nagy A, Schally AV, Halmos G, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A. 1998;95:1794-1799.
5. Benali N, Cordelier P, Calise D, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A. 2000;97:9180-9185.
6. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-Iabeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
7. 3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763-769.
8. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
9. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem. 2003;90:509-517.
10. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-366.
11. Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res. 2005;11:139-146.
12. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
13. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2:299-305.
14. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 2001;171:153-164.
15. Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 2002;184:127-147.
16. Wellings DA, Atherton E. Standard Fmoc protocols. Methods Enzymol. 1997;289:44-67.
17. Crim JW, Garczynski SF, Brown MR. Approaches to radioiodination of insect neuropeptides. Peptides. 2002;23:2045-2051.
18. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
19. Schmidt K, Hoffend J, Altmann A, et al. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res. 2005;11:2132-2140.
20. Kuhnast B, Bodenstein C, Haubner R, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol. 2004;31:337-344.
21. Askoxylakis V, Zitzmann S, Mier W, et al. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res. 2005;11:6705-6712.
22. Behe M, Du J, Becker W, et al. Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate. Med Oncol. 2001;18:59-64.
23. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 1984;309:30-33.
24. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.
25. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62:5139-5143.
26. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004;45:1776-1783.
27. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
28. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
29. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-6151.
30. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res. 2003;9:4505-4513.